Joseph Catanzaro
Stock Analyst at Mizuho
(3.98)
# 813
Out of 5,182 analysts
105
Total ratings
48.91%
Success rate
12.65%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Initiates: Outperform | $18 | $9.26 | +94.38% | 1 | Apr 15, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $105 → $110 | $85.37 | +28.85% | 2 | Mar 30, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $12 | $4.12 | +191.26% | 7 | Mar 23, 2026 | |
| ERAS Erasca | Maintains: Outperform | $16 → $19 | $9.90 | +91.92% | 1 | Mar 13, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $20 | $25.14 | -20.45% | 3 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $8.56 | +203.74% | 1 | Mar 2, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $17.08 | +104.92% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $6.96 | +0.57% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $144.83 | -1.26% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $12.86 | +203.27% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $51 | $9.51 | +436.28% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $21.92 | -17.88% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $68.63 | -22.77% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $83.85 | +43.11% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $33.23 | +44.45% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.38 | +77.51% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.24 | +267.65% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $129.26 | -14.90% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $44.93 | -15.42% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $11.37 | +31.93% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $63.86 | -17.01% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.68 | +495.24% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.53 | +1,141.83% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $11.59 | +63.93% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.70 | +455.56% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $9.29 | +287.51% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.32 | +60.94% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.51 | +79.28% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.90 | +1,478.95% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.44 | +1,288.89% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.26 | -22.69% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $29.44 | -32.07% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.40 | -37.50% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $29.11 | +587.05% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $15.02 | +133.02% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.42 | +4,125.35% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.54 | +608.66% | 3 | Apr 7, 2020 |
Climb Bio
Apr 15, 2026
Initiates: Outperform
Price Target: $18
Current: $9.26
Upside: +94.38%
Apogee Therapeutics
Mar 30, 2026
Maintains: Outperform
Price Target: $105 → $110
Current: $85.37
Upside: +28.85%
CytomX Therapeutics
Mar 23, 2026
Maintains: Overweight
Price Target: $10 → $12
Current: $4.12
Upside: +191.26%
Erasca
Mar 13, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $9.90
Upside: +91.92%
Tango Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $19 → $20
Current: $25.14
Upside: -20.45%
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $8.56
Upside: +203.74%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $17.08
Upside: +104.92%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $6.96
Upside: +0.57%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $144.83
Upside: -1.26%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $12.86
Upside: +203.27%
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $9.51
Upside: +436.28%
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $21.92
Upside: -17.88%
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $68.63
Upside: -22.77%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $83.85
Upside: +43.11%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $33.23
Upside: +44.45%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.38
Upside: +77.51%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.24
Upside: +267.65%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $129.26
Upside: -14.90%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $44.93
Upside: -15.42%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $11.37
Upside: +31.93%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $63.86
Upside: -17.01%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.68
Upside: +495.24%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.53
Upside: +1,141.83%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $11.59
Upside: +63.93%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.70
Upside: +455.56%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $9.29
Upside: +287.51%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.32
Upside: +60.94%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.51
Upside: +79.28%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.90
Upside: +1,478.95%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.44
Upside: +1,288.89%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.26
Upside: -22.69%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $29.44
Upside: -32.07%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.40
Upside: -37.50%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $29.11
Upside: +587.05%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $15.02
Upside: +133.02%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.42
Upside: +4,125.35%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.54
Upside: +608.66%